Glaukos Q3 2023 Earnings Report $150.88 +7.14 (+4.97%) (As of 12/20/2024 05:40 PM ET) Earnings HistoryForecast Glaukos EPS ResultsActual EPS-$0.50Consensus EPS -$0.56Beat/MissBeat by +$0.06One Year Ago EPS-$0.45Glaukos Revenue ResultsActual Revenue$78.05 millionExpected Revenue$75.25 millionBeat/MissBeat by +$2.80 millionYoY Revenue Growth+9.50%Glaukos Announcement DetailsQuarterQ3 2023Date11/1/2023TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseGKOS Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by ⭕ [URGENT] Buy Alert just triggered (Ad)My absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Glaukos Earnings HeadlinesThe three-year returns have been stellar for Glaukos (NYSE:GKOS) shareholders despite underlying losses increasingDecember 21 at 6:21 PM | au.finance.yahoo.comGlaukos: Still Bullish, But Embedded Expectations Are Now HighDecember 21 at 8:07 AM | seekingalpha.com⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.December 22, 2024 | Behind the Markets (Ad)Glaukos (NYSE:GKOS) Hits New 12-Month High on Analyst UpgradeDecember 21 at 1:17 AM | americanbankingnews.comGlaukos (GKOS) Receives a Buy from Stifel NicolausDecember 20 at 6:38 PM | markets.businessinsider.comShort Interest in Glaukos Co. (NYSE:GKOS) Declines By 5.3%December 19 at 2:31 AM | americanbankingnews.comSee More Glaukos Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Glaukos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Glaukos and other key companies, straight to your email. Email Address About GlaukosGlaukos (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.View Glaukos ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
